Bristol Myers Squibb to buy RayzeBio for $4.1 billion in cash
Bristol Myers Squibb (BMY), a leading biopharmaceutical company, announced today that it has agreed to acquire RayzeBio (RYZB), a clinical-stage company developing novel radiopharmaceutical therapies for solid tumors, for $62.50 per share in cash, or $4.1 billion in total. The…